PRESS RELEASE: Sign Up for a Complimentary Trial of Inside Health Policy that Expires Automatically after 30 Days
Contact: Steve Reilly
WASHINGTON, DC USA -- HEALTHCARE UPDATE NEWS SERVICE -- MAY 30, 2023: Inside Health Policy delivers reporting you won't find elsewhere — forward-looking news essential for insurers, health care providers, hospitals and other health policy professionals, including pharmaceutical and medical device manufacturers, lawmakers and other government officials, lawyers, consultants and policy advisers.
Sign up for a free trial subscription to Inside Health Policy, the online news service on health care policy from the regulatory reporting experts at Inside Washington Publishers.
Here is a sample of the latest Inside Health Policy stories covering Artificial Intelligence, the hottest issue in healthcare. You can read these stories, and many more, with your free trial:
- Expert: FDA's MAUDE Database Can't Track Bias In AI/ML Health Tech
FDA's Manufacturer and User Facility Device Experience database is insufficient in monitoring bias in artificial intelligence and machine learning health technologies, according to experts, as federal agencies and lawmakers scramble to monitor the rapid expansion of AI/ML systems in the health care sector. FDA and the Federal Trade Commission are in the process of drafting new regulatory requirements to eliminate bias in AI/ML technologies bias before and after devices and software are on market as the technologies' use in the health sector rapidly expands.
- Google Health Leader Cites Major Leaps In Use Of AI For Mental Health Advice
Artificial intelligence (AI) tools Google uses across its health-related products, including to provide suggested resources to users whose searches indicate a mental health crisis, have significantly improved and are now better able to translate users' information consumption into helpful recommendations, an official with Google Health said.
- FTC Warns Misuse Of AI, Machine Learning Info Could Violate FTC Act
FTC warned Thursday (May 18) that increasing use of consumers' biometric information and related technologies, like those powered by artificial intelligence/machine learning, significantly elevates consumer privacy and data security concerns and the potential for bias and discrimination, and could be illegal. False or unsubstantiated claims about the accuracy or efficacy of biometric information technologies or about the collection and use of biometric information could violate the FTC Act, the agency says.
- FDA Seeks Input On How To Evaluate AI In Drug Development
FDA is seeking feedback from stakeholders on how to regulate the use of artificial intelligence (AI) and machine learning (ML) in drug development, with an aim to promote collaborative discussion as the number of submissions that involve the technologies increases.
You can try Inside Health Policy for the next month with absolutely no obligation, your trial will simply expire at the end of 30 days. Your trial to Inside Health Policy includes online access to the newsletter you choose: Inside CMS, FDA Week, Health Exchange Alert, Inside Drug Pricing, or Inside TeleHealth - and please call us if you want access to a second newsletter with your trial. Plus, if you choose to subscribe, we’ll offer you 50% off for the first year of access.
FOR E-MAIL ADDRESS CHANGE, ADD OR DELETE REQUESTS:
For more information about the 50% off, first-year savings, contact Steve Reilly at 703-562-8992, or e-mail him at firstname.lastname@example.org.
For changes or additions, please email your request to: listmgrbm@HealthCareUpdateNewsService.com.
For removal of your e-mail address, please click the "SafeUnsubscribe" link located in the footer of this message below to automatically remove your address from the list.